CRDF
Cardiff Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.39
+6.92%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.29
From 52W high−56.70%
Volume586247.00
Market cap$108.14M
P/E (TTM)—
P/S (TTM)212.9x
Div yield—
Key dataSep 18, 2026
Open
$1.29
From 52W high
−56.70%
Volume
586247.00
Market cap
$108.14M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.9x
P/E (TTM)
—
RSI (14)
68.7
MomentumView details →
1D Return
+6.92%
YTD Return
−53.20%
SummaryUpdated Jun 1, 2026
Cardiff Oncology, Inc. (NASDAQ:CRDF) is a clinical-stage biotechnology company founded in 1999 and headquartered in San Diego, California. Originally incorporated as Trovagene, Inc., the company changed its name to Cardiff Oncology in May 2012 to reflect its focused mission on developing innovative cancer treatments. The company went public in 2004 and has since dedicated itself to advancing novel therapeutic approaches for cancer patients, with a particular emphasis on targeting specific molecular pathways that drive tumor growth and resistance to existing treatments.
Similar companies
Latest newsMore news →
Cardiff Oncology and Nerviano Medical Sciences signed a confidential settlement agreement on September 14, 2026 to dismiss their litigation with prejudice and exchange mutual releases, with no monetary payment or admission of liability.6d agoCardiff Oncology and Nerviano Medical Sciences amended their 2017 exclusive license agreement.6d agoCardiff Oncology presented positive Phase 2 CRDF-004 data at ASCO supporting advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into a planned registrational program for first-line RAS-mutated metastatic colorectal cancer.40d ago